Bristol-Myers Squibb (BMY) Crosses Pivot Point Resistance at $34.57 Financial News Network Online The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders. By Peter Chu. |
